{
    "clinical_study": {
        "@rank": "144721", 
        "arm_group": [
            {
                "arm_group_label": "Free laxative CTC", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Low-dose laxative bowel preparation for CTC", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate a low-dose of bowel preparation for Computed Tomography\n      Colonography (CTC) versus free laxative CTC with regard to performance, feasibility, patient\n      tolerability and acceptance."
        }, 
        "brief_title": "Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": "Gastrointestinal Complication", 
        "detailed_description": {
            "textblock": "Computed Tomography Colonography (CTC) is a valid alternative to colonoscopy in the\n      detection of cancer, polyps and other colon lesions.\n\n      High volume cathartic preparations, low volume cathartic solutions with oral tagging agent\n      and tagging agent only are the procedures available for CTC.\n\n      High volume preparations are a considerable burden for patients. Low volume cathartic\n      solutions are more accepted by the patients, reduce the amount of tagging agent and the\n      waiting time to the exam. Tagging agent only preparations represent a risk if they are taken\n      without medical supervision."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Out-patients undergoing a CTC\n\n          -  Patient written informed consent\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women or at a risk of becoming pregnant\n\n          -  Known or suspected gastrointestinal obstruction or perforation, toxic megacolon,\n             ileo, major colonic surgery\n\n          -  History of anaphylaxis to Iopamidol or allergic reactions to drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040285", 
            "org_study_id": "CTC-Prep 1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low-dose laxative bowel preparation for CTC", 
                "description": "the day before the CTC:\nlow fiber diet\nat 15.00: 2 tablets of bisacodyl (5 mg)\nat 17.00: 1 litre of PEG-CS\nliquid diet\nthe day of the exam:\nat home: 2 tablets of bisacodyl (5 mg)\nat the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water\nat the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im", 
                "intervention_name": "Bisacodyl & PEG-CS", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lovoldyl (Bisacodyl)", 
                    "Lovolesse (PEG-CS)", 
                    "Gastromiro (Iopamidol)", 
                    "Plasil (Metoclopramide mono chlorohydrate monohydrate)"
                ]
            }, 
            {
                "arm_group_label": "Free laxative CTC", 
                "description": "the day before CTC:\nlow fiber diet\nat 15.00: 90 ml of Iopamidol in 250 ml of water\nat 17.00: 90 ml of Iopamidol in 250 ml of water\nat 20.00: start liquid diet", 
                "intervention_name": "Iopamidol", 
                "intervention_type": "Drug", 
                "other_name": "Gastromiro (Iopamidol)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bisacodyl", 
                "Cathartics", 
                "Metoclopramide", 
                "Laxatives"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "CT colonography", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Roma", 
                    "country": "Italy"
                }, 
                "name": "Policlinico Umberto I"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC). Comparison vs Laxative Free CTC.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Tagging. In prone and supine position, each colon segment (caecum, ascending, transverse, descending, sigma and rectum) will be graded by using a 4 point scale (from 0= greater than 75% of residuals to 3=  minor than 25% of residuals).", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "20 min"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040285"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Policlinico Umberto I", 
            "investigator_full_name": "Andrea Laghi", 
            "investigator_title": "Prof., MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Residual fluid evaluation. In prone and supine position, each colon segment (caecum, ascending, transverse, descending, sigma and rectum) will be graded by using a 4 point scale (from 1= minor than 25% of the ap axis to 4= greater than 75% of the ap axis).", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "20 minutes"
            }, 
            {
                "description": "Bowel distension. In prone and supine position, each colon segment (caecum, ascending, transverse, descending, sigma and rectum) will be graded by using a 4 point scale (from 0= greater than 75% of the maximal distension to 3= minor than 25% of the maximal distension)", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "20 min"
            }, 
            {
                "description": "Recording of all Adverse Events (AEs) occurring during the 2 days of treatment", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "2 days (the day before and the day of CTC)"
            }, 
            {
                "description": "Tolerability. Recording of gastrointestinal (GI) symptoms occurring during the 2 days of treatment. Intensity of GI symptoms will be evaluated by a Visual Analgic Scale (VAS) ranging from 0=no symptoms to 10=severe, as much as possible.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "2 days (the day before and the day of the exam)"
            }, 
            {
                "description": "Evaluation of the patient discomfort related to bowel preparation. A 4 point scale is used: 1=none; 2=mild distress; 3=moderate distress; 4=severe distress.", 
                "measure": "Acceptability", 
                "safety_issue": "No", 
                "time_frame": "2 days (the day before and the day of the exam)"
            }
        ], 
        "source": "Azienda Policlinico Umberto I", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Azienda Policlinico Umberto I", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}